Which medication would be used to treat patent ductus arteriosus (PDA) in neonates?

Which medication would be used to treat patent ductus arteriosus (PDA) in neonates?

• A. Ibuprofen
• B. Indomethacin
• C. Acetaminophen
• D. Furosemide

Answer: (B)

Indomethacin is commonly used to treat patent ductus arteriosus (PDA) in neonates due to its ability to inhibit the production of prostaglandins, which are responsible for maintaining the patency of the ductus arteriosus. By reducing prostaglandin levels, indomethacin promotes the closure of the ductus arteriosus, which can be essential in cases where the ductus remains open and contributes to complications such as heart failure or respiratory distress. While ibuprofen can also be used for PDA treatment, indomethacin is specifically noted for its historical first-line role in this context. Acetaminophen is primarily used for pain relief and fever control and does not address the underlying issue of a patent ductus arteriosus. Furosemide is a diuretic used to manage fluid overload and is not indicated for the closure of PDA. Thus, indomethacin stands out as the preferred choice for treating patent ductus arteriosus in neonates.

Indomethacin is commonly used to treat patent ductus arteriosus (PDA) in neonates due to its ability to inhibit the production of prostaglandins, which are responsible for maintaining the patency of the ductus arteriosus. By reducing prostaglandin levels, indomethacin promotes the closure of the ductus arteriosus, which can be essential in cases where the ductus remains open and contributes to complications such as heart failure or respiratory distress.

While ibuprofen can also be used for PDA treatment, indomethacin is specifically noted for its historical first-line role in this context. Acetaminophen is primarily used for pain relief and fever control and does not address the underlying issue of a patent ductus arteriosus. Furosemide is a diuretic used to manage fluid overload and is not indicated for the closure of PDA. Thus, indomethacin stands out as the preferred choice for treating patent ductus arteriosus in neonates.